Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab and Chemotherapy in Muscle-Invasive Urothelial Cancer
NCT02365766Phase 2Completed
- Start
- May 2015
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in urothelial carcinoma (UC). Started May 2015; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02365766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365766.